953769-46-5

Basic information

• Product Name: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide
• Synonyms: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide;BLZ945;4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide BLZ945;4-[[2-[[(1R,2R)-2-Hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methyl-2-pyridinecarboxamide;BLZ-945 >=95%
• CAS NO: 953769-46-5
• Molecular Formula: C20H22N4O3S
• Molecular Weight: 398.47868
• Product Categories: Inhibitors
• Mol File: 953769-46-5.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.377±0.06 g/cm3(Predicted)
• Solubility: insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL in DMSO
• PKA: 13.92±0.46(Predicted)
• CAS DataBase Reference: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide(953769-46-5)
• EPA Substance Registry System: 4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide(953769-46-5)

Safety Data

• Hazardous Substances Data: 953769-46-5(Hazardous Substances Data)

Usage

Description

4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide, also known as BLZ945, is a novel compound with a complex chemical structure. It is characterized by the presence of a cyclohexane ring with two hydroxyl groups in the 1R,2R configuration, an amino group attached to a benzothiazole moiety, and a methylpicolinamide group. This unique structure endows BLZ945 with specific properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
BLZ945 is used as a tumor-associated macrophage targeting agent for the treatment of glioblastoma multiforme, the most common and aggressive type of brain cancer. Its unique structure allows it to selectively target and modulate the activity of tumor-associated macrophages, which play a crucial role in tumor progression and resistance to therapy. By targeting these macrophages, BLZ945 has the potential to enhance the efficacy of conventional cancer treatments and improve patient outcomes.
In addition to its primary application in glioblastoma treatment, the unique structure and properties of BLZ945 may also make it a promising candidate for other therapeutic applications. Its ability to modulate the activity of immune cells, such as macrophages, could potentially be harnessed to treat other types of cancer or inflammatory diseases. Further research and development are needed to fully explore the potential applications of this novel compound.